Welcome to our dedicated page for Veraxa Biotech Holding SEC filings (Ticker: VRXA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Veraxa Biotech Holding's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Veraxa Biotech Holding's regulatory disclosures and financial reporting.
VERAXA Biotech AG reported that it has strengthened its intellectual property around its BiTAC cancer therapy platforms. In the first half of 2026, the company filed initial patent applications for its T cell engager (BiTAC-TCE) and antibody-drug-conjugate (BiTAC-ADC) technologies and related therapeutic programs, while previously granted auxiliary technology patents have cleared their opposition period.
VERAXA now has more than 50 granted owned or exclusively licensed patents in 14 countries, spread across 26 patent families, and expects recently filed applications, once granted, to protect its core technology suite through at least 2047. The BiTAC approach uses dual-component constructs and click-chemistry-based "click-to-release" payload activation to enhance tumor selectivity, safety, and manufacturability of next-generation antibody-based therapies.
Veraxa Biotech AG reported that its bispecific antibody drug conjugate program VXA-222, developed under a joint discovery alliance with OmniAb, Inc., has achieved a key technical milestone and is moving into its next collaboration phase after OmniAb concluded its discovery work.
VXA-222 applies an “AND-gate” logic, targeting two different antigens on solid tumors with a single molecule. The collaboration, established in May 2025, combines OmniAb’s transgenic antibody discovery technologies with Veraxa’s proprietary ADC linker and conjugation platform. Veraxa will now establish the bsADC lead candidate, conduct in vitro and in vivo validation, and holds exclusive rights to develop and commercialize products using OmniAb-derived antibodies, while OmniAb is entitled to a share of specified revenue. Veraxa highlights this as part of its broader strategy to advance next-generation antibody-based cancer therapeutics.
Veraxa Biotech AG reports that shareholders at the 24 July 2026 Extraordinary General Meeting approved all Board proposals, with more than 99.94% of votes cast on 102,102,301 voting shares, representing 72.20% of share capital. The amendments are intended to support long-term growth and strategic flexibility.
The Articles state share capital of CHF 1,248,634 + 50/453, divided into 141,407,813 registered shares with a par value of CHF 100/11,325 each. New authorizations add conditional share capital for equity-linked instruments, merger-related options, and employee and advisory plans, plus a capital band permitting issuance of up to 70,662,564 additional shares until 31 December 2030, in defined cases with excluded or limited subscription rights.
Governance changes include increasing the maximum Board size from five to seven and detailed rules on compensation approval, stock-based incentives and outside mandates. Veraxa also highlighted progress on its BiTAC T-cell engager program and named Carl von Halem interim CFO and Christoph Erkel, Ph.D. as Chief Scientific Officer.
Veraxa Biotech AG reported new in vitro proof-of-concept data validating its novel BiTAC-ADC technology platform for more precise, tumor-restricted cancer treatment. In studies, BiTAC-ADCs discriminated between breast cancer and healthy cells and showed efficient, dose-dependent killing of 3D tumor cell spheroids.
The platform uses two complementary antibody-delivered precursors to keep payloads inactive in circulation and activate them only inside tumor cells, aiming to reduce off-tumor toxicity. Veraxa will attend the BIO International Convention in San Diego from June 22-25, 2026 to discuss partnering opportunities for its BiTAC-ADC and BiTAC-TCE platforms.
Veraxa Biotech filed a Shell Company Report on Form 20-F following its business combination with Voyager Acquisition Corp., creating a Nasdaq-listed Swiss oncology biotech focused on antibody therapies. The company now operates mainly through VERAXA Biotech GmbH in Heidelberg and positions itself around ADCs and T cell engagers.
Veraxa reported 2025 revenue of ₣23,426 from antibody-related projects and a net loss of ₣66.6 million, driven largely by stock-based compensation and rising R&D and marketing costs. Pro forma as of December 31, 2025, total indebtedness was ₣25,384 thousand and shareholders’ equity was negative at ₣26,634 thousand, reflecting its early-stage profile.
To support liquidity, Veraxa completed a $27.5 million senior secured note and warrant financing with High Trail Capital and put in place a $50 million equity purchase commitment with Lincoln Park Capital. The filing also details an extensive global patent and trademark portfolio underpinning its microfluidics, genetic code expansion and BiTAC-TCE platforms, as well as equity-based incentive plans and Swiss-governed corporate structures as a foreign private issuer and emerging growth company.
European Molecular Biology Laboratory filed a Schedule 13D reporting beneficial ownership of 22,891,235 Veraxa Biotech Holding AG ordinary shares, representing 16.2% of the class. The stake was acquired in connection with the June 8, 2026 business combination between Voyager Acquisition Corp. and Veraxa Biotech AG.
The shares were obtained for investment purposes, and the holder may increase or reduce its position over time. Certain shares are subject to a voting, support and lock-up agreement that restricts transfers for a period after closing. Company shareholders may also receive up to 5,000,000 additional earnout shares if future volume-weighted average price targets are met by dates through 2028.
Veraxa Biotech Holding AG shareholder David Lukas Deck reports beneficial ownership of 25,502,836 ordinary shares, representing 18.0% of the class. These shares were acquired upon completion of a business combination among Voyager Acquisition Corp. and Veraxa entities on June 8, 2026.
Deck holds sole voting and dispositive power over these shares and describes the position as held for investment purposes, while reserving flexibility to buy or sell in the future. He is also subject to a voting, support and lock-up agreement that restricts transfers of certain shares for a period after closing.
Company shareholders may receive up to 5,000,000 additional Earnout Shares if the volume-weighted average price of Veraxa’s ordinary shares meets VWAP hurdles of $11.00, $12.50 and $14.00 for specified 20-out-of-30 trading-day periods before December 31 of 2026, 2027 and 2028, respectively.
Xlife Sciences AG reports beneficial ownership of 23,029,967 Veraxa Biotech Holding AG ordinary shares, representing 16.3% of the class. These shares were acquired in a multi-step business combination among Voyager Acquisition Corp., Veraxa entities and PubCo, which was later renamed Veraxa Biotech AG.
Xlife holds sole voting and dispositive power over these shares and characterizes the position as an investment. Its stake is subject to a Voting, Support and Lock-Up Agreement that restricts transfers of certain shares for a period after closing. Company shareholders may also receive up to 5,000,000 additional earnout shares if Veraxa’s volume‑weighted average price meets specified price hurdles of $11.00, $12.50 and $14.00 by year-end 2026, 2027 and 2028, respectively.
Gilbert Edgar Schoeni filed a Schedule 13D reporting a significant ownership position in Veraxa Biotech Holding AG following a business combination with Voyager Acquisition Corp. He reports beneficial ownership of 22,539,749 ordinary shares, representing 15.9% of the class, with sole voting and dispositive power over these shares.
The shares were acquired in connection with the closing of the business combination completed on June 8, 2026, under a Business Combination Agreement among Voyager, Veraxa entities and other parties. Schoeni states the shares are held for investment purposes but may be increased or reduced depending on market and company factors.
Under a Voting, Support and Lock-Up Agreement, certain PubCo ordinary shares are restricted from transfer for a specified period after closing, subject to exceptions. Company shareholders may also receive up to 5,000,000 additional earnout shares if volume-weighted average price conditions of $11.00, $12.50 and $14.00 are met by dates through December 31, 2028.
Veraxa Biotech AG has completed its business combination with Voyager Acquisition Corp., creating a publicly traded oncology-focused biotech on Nasdaq. The combined company is named Veraxa Biotech AG and will begin trading its ordinary shares under the symbol “VRXA” and its warrants under “VRXAW” on June 11, 2026.
The company highlights a pipeline of next-generation bispecific T-cell engagers (TCEs) and antibody-drug conjugates (ADCs) built on its proprietary BiTAC platform, designed to target tumor cells expressing two antigens while sparing healthy tissue. Initial preclinical data from its lead BiTAC program, presented at the AACR 2026 meeting, showed the candidate attacking dual-target cancer cells while sparing single-target cells, with a superior safety profile and comparable efficacy to a traditional TCE, suggesting potential for an improved therapeutic index.
Veraxa also notes that proceeds from recent financings, including a senior secured note of $27.5 million and a securities purchase agreement of up to $50 million, are expected to support advancement of its BiTAC-TCE and BiTAC-ADC programs toward clinical development and early value milestones.